[go: up one dir, main page]

AU2001226029A1 - Pharmaceutical formulation and method for pulmonary and oral delivery - Google Patents

Pharmaceutical formulation and method for pulmonary and oral delivery

Info

Publication number
AU2001226029A1
AU2001226029A1 AU2001226029A AU2602901A AU2001226029A1 AU 2001226029 A1 AU2001226029 A1 AU 2001226029A1 AU 2001226029 A AU2001226029 A AU 2001226029A AU 2602901 A AU2602901 A AU 2602901A AU 2001226029 A1 AU2001226029 A1 AU 2001226029A1
Authority
AU
Australia
Prior art keywords
pulmonary
pharmaceutical formulation
oral delivery
oral
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001226029A
Inventor
Robert Schultz
Gary Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dura Pharmaceuticals Inc
Original Assignee
Dura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dura Pharmaceuticals Inc filed Critical Dura Pharmaceuticals Inc
Publication of AU2001226029A1 publication Critical patent/AU2001226029A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
AU2001226029A 2000-01-10 2000-12-28 Pharmaceutical formulation and method for pulmonary and oral delivery Abandoned AU2001226029A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48054900A 2000-01-10 2000-01-10
US09480549 2000-01-10
PCT/US2000/035427 WO2001051030A1 (en) 2000-01-10 2000-12-28 Pharmaceutical formulation and method for pulmonary and oral delivery

Publications (1)

Publication Number Publication Date
AU2001226029A1 true AU2001226029A1 (en) 2001-07-24

Family

ID=23908389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001226029A Abandoned AU2001226029A1 (en) 2000-01-10 2000-12-28 Pharmaceutical formulation and method for pulmonary and oral delivery

Country Status (3)

Country Link
US (1) US6616914B2 (en)
AU (1) AU2001226029A1 (en)
WO (1) WO2001051030A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL352615A1 (en) 1999-06-05 2003-08-25 Innovata Biomed Ltd Delivery system
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
AU2003225777B2 (en) * 2002-03-12 2008-04-10 Microdose Therapeutx, Inc. Site specific delivery of co-administered drugs via inhalation
AU2003226603A1 (en) * 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
EP1599209B1 (en) * 2002-08-21 2011-08-17 Norton Healthcare Limited Inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008137960A1 (en) * 2007-05-07 2008-11-13 Questor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
SI2565193T1 (en) 2009-01-23 2014-07-31 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CA2762987A1 (en) 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
CN102665807A (en) 2010-01-05 2012-09-12 微剂量治疗技术公司 Inhalation device and method
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
AU2011210352A1 (en) 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
PT3415139T (en) 2011-06-14 2022-06-20 Neurelis Inc Administration of benzodiazepine
EP2828241B1 (en) 2012-03-23 2018-09-12 Mateon Therapeutics, Inc. Compositions and methods for inhibition of cathepsins
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
MX2022001596A (en) 2019-08-08 2022-03-11 Rigel Pharmaceuticals Inc COMPOUNDS AND METHODS TO TREAT CYTOKINE RELEASE SYNDROME.
ES2970382T3 (en) 2019-08-14 2024-05-28 Rigel Pharmaceuticals Inc Method to block or improve cytokine release syndrome
US11116737B1 (en) * 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
JP2025513716A (en) 2022-03-23 2025-04-30 ライジェル・ファーマシューティカルズ・インコーポレイテッド Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
BR0010262A (en) * 1999-05-03 2002-01-15 Battelle Memorial Institute Composition to form an aerosol, process for preparing and aerosolizing a composition, and aerosol generating device

Also Published As

Publication number Publication date
US6616914B2 (en) 2003-09-09
WO2001051030A1 (en) 2001-07-19
US20010041190A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
AU2001280188A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2002319653A1 (en) Method for oral drug delivery
AU3403201A (en) Drug delivery device and method
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002239397A1 (en) Drug formulation having improved oral tolerability
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2002354476A1 (en) Pyrazolopyridine derivatives and medicinal use thereof
AU2001284444A1 (en) Preparations for oral administration
GB2355656B (en) Pharmaceutical compositions for oral and topical administration
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU3201701A (en) Pharmaceutical composition for pulmonary delivery
AU2001252741A1 (en) Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
AU2002334123A1 (en) Anaesthetic compositions and method for their administration
AU5072000A (en) Pharmaceutical composition for nasally administering water-soluble active substances
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU3926000A (en) Methods and compositions for drug delivery
AU2570001A (en) Pharmaceutical composition and method for its manufacture
AU5415699A (en) Water-soluble pharmaceutical formulation for administering sildenafil
AU4876701A (en) Peptide derivatives and medicinal compositions
AU2001258714A1 (en) Herbal composition useful for treatment or oral cavity and method for its local delivery thereof
AU5483600A (en) Pharmaceutical materials and methods for their preparation and use
AU2001259564A1 (en) Pharmaceutical compositions and methods for use